vs
Paysign, Inc.（PAYS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Paysign, Inc.的1.3倍（$30.3M vs $22.8M），Paysign, Inc.净利率更高（6.0% vs -221.3%，领先227.3%），Paysign, Inc.同比增速更快（45.8% vs 43.0%），Paysign, Inc.自由现金流更多（$47.5M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 31.3%）
Paysign, Inc.是一家专业支付解决方案提供商，主打定制化预付卡项目、端到端支付处理服务及数字发放工具，核心服务领域覆盖医疗保健、企业激励与大众消费市场，主要业务和客户群体分布于北美地区。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PAYS vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$22.8M
营收增速更快
PAYS
高出2.8%
43.0%
净利率更高
PAYS
高出227.3%
-221.3%
自由现金流更多
PAYS
多$100.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.8M | $30.3M |
| 净利润 | $1.4M | $-67.1M |
| 毛利率 | 57.7% | — |
| 营业利润率 | 8.1% | -190.0% |
| 净利率 | 6.0% | -221.3% |
| 营收同比 | 45.8% | 43.0% |
| 净利润同比 | -0.7% | -31.2% |
| 每股收益（稀释后） | $0.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAYSRGNX
| Q4 25 | $22.8M | $30.3M | ||
| Q3 25 | $21.6M | $29.7M | ||
| Q2 25 | $19.1M | $21.4M | ||
| Q1 25 | $18.6M | $89.0M | ||
| Q4 24 | $15.6M | $21.2M | ||
| Q3 24 | $15.3M | $24.2M | ||
| Q2 24 | $14.3M | $22.3M | ||
| Q1 24 | $13.2M | $15.6M |
净利润PAYSRGNX
| Q4 25 | $1.4M | $-67.1M | ||
| Q3 25 | $2.2M | $-61.9M | ||
| Q2 25 | $1.4M | $-70.9M | ||
| Q1 25 | $2.6M | $6.1M | ||
| Q4 24 | $1.4M | $-51.2M | ||
| Q3 24 | $1.4M | $-59.6M | ||
| Q2 24 | $697.1K | $-53.0M | ||
| Q1 24 | $309.1K | $-63.3M |
毛利率PAYSRGNX
| Q4 25 | 57.7% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 61.6% | — | ||
| Q1 25 | 62.9% | — | ||
| Q4 24 | 58.9% | 70.2% | ||
| Q3 24 | 55.5% | 48.8% | ||
| Q2 24 | 52.9% | 52.5% | ||
| Q1 24 | 52.6% | 72.6% |
营业利润率PAYSRGNX
| Q4 25 | 8.1% | -190.0% | ||
| Q3 25 | 7.3% | -176.3% | ||
| Q2 25 | 7.5% | -296.3% | ||
| Q1 25 | 13.4% | 13.6% | ||
| Q4 24 | 3.0% | -242.1% | ||
| Q3 24 | 4.5% | -256.6% | ||
| Q2 24 | 0.9% | -251.3% | ||
| Q1 24 | -2.0% | -408.8% |
净利率PAYSRGNX
| Q4 25 | 6.0% | -221.3% | ||
| Q3 25 | 10.3% | -208.3% | ||
| Q2 25 | 7.3% | -331.8% | ||
| Q1 25 | 13.9% | 6.8% | ||
| Q4 24 | 8.8% | -241.3% | ||
| Q3 24 | 9.4% | -246.3% | ||
| Q2 24 | 4.9% | -237.7% | ||
| Q1 24 | 2.3% | -405.4% |
每股收益（稀释后）PAYSRGNX
| Q4 25 | $0.02 | $-1.30 | ||
| Q3 25 | $0.04 | $-1.20 | ||
| Q2 25 | $0.02 | $-1.38 | ||
| Q1 25 | $0.05 | $0.12 | ||
| Q4 24 | $0.02 | $-0.99 | ||
| Q3 24 | $0.03 | $-1.17 | ||
| Q2 24 | $0.01 | $-1.05 | ||
| Q1 24 | $0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.5M | $102.7M |
| 总资产 | $276.3M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PAYSRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益PAYSRGNX
| Q4 25 | $48.5M | $102.7M | ||
| Q3 25 | $45.8M | $161.5M | ||
| Q2 25 | $42.2M | $213.7M | ||
| Q1 25 | $39.3M | $274.2M | ||
| Q4 24 | $30.4M | $259.7M | ||
| Q3 24 | $28.5M | $301.4M | ||
| Q2 24 | $26.9M | $348.3M | ||
| Q1 24 | $25.5M | $390.7M |
总资产PAYSRGNX
| Q4 25 | $276.3M | $453.0M | ||
| Q3 25 | $209.5M | $525.2M | ||
| Q2 25 | $193.9M | $581.0M | ||
| Q1 25 | $205.1M | $490.9M | ||
| Q4 24 | $179.0M | $466.0M | ||
| Q3 24 | $167.0M | $519.1M | ||
| Q2 24 | $182.3M | $569.4M | ||
| Q1 24 | $173.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $47.5M | $-52.8M |
| 自由现金流率自由现金流/营收 | 208.7% | -174.0% |
| 资本支出强度资本支出/营收 | 2.6% | 1.7% |
| 现金转化率经营现金流/净利润 | 35.29× | — |
| 过去12个月自由现金流最近4个季度 | $51.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PAYSRGNX
| Q4 25 | $48.1M | $-52.3M | ||
| Q3 25 | $6.8M | $-56.0M | ||
| Q2 25 | $3.6M | $-49.3M | ||
| Q1 25 | $-6.0M | $33.6M | ||
| Q4 24 | $14.3M | $-31.6M | ||
| Q3 24 | $-20.2M | $-40.5M | ||
| Q2 24 | $20.6M | $-45.5M | ||
| Q1 24 | $8.2M | $-55.5M |
自由现金流PAYSRGNX
| Q4 25 | $47.5M | $-52.8M | ||
| Q3 25 | $6.3M | $-56.5M | ||
| Q2 25 | $3.6M | $-49.7M | ||
| Q1 25 | $-6.1M | $32.6M | ||
| Q4 24 | $14.2M | $-32.7M | ||
| Q3 24 | $-20.3M | $-40.9M | ||
| Q2 24 | $20.4M | $-46.0M | ||
| Q1 24 | $8.2M | $-56.0M |
自由现金流率PAYSRGNX
| Q4 25 | 208.7% | -174.0% | ||
| Q3 25 | 29.2% | -189.9% | ||
| Q2 25 | 18.6% | -232.8% | ||
| Q1 25 | -32.9% | 36.6% | ||
| Q4 24 | 91.0% | -154.2% | ||
| Q3 24 | -133.0% | -168.9% | ||
| Q2 24 | 142.4% | -206.2% | ||
| Q1 24 | 62.1% | -358.5% |
资本支出强度PAYSRGNX
| Q4 25 | 2.6% | 1.7% | ||
| Q3 25 | 2.1% | 1.7% | ||
| Q2 25 | 0.5% | 1.8% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 0.7% | 5.1% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 1.0% | 2.1% | ||
| Q1 24 | 0.4% | 3.6% |
现金转化率PAYSRGNX
| Q4 25 | 35.29× | — | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 2.62× | — | ||
| Q1 25 | -2.33× | 5.53× | ||
| Q4 24 | 10.43× | — | ||
| Q3 24 | -14.03× | — | ||
| Q2 24 | 29.48× | — | ||
| Q1 24 | 26.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAYS
| Plasma Industry | $12.6M | 55% |
| Pharma Industry | $9.6M | 42% |
| Other | $558.4K | 2% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
